The Adamant Health measurement and analysis service complements clinical assessment and helps clinicians get a more holistic view of a patient’s condition by collecting symptom data over an extended period of time and at home.

Riaz has been living with Parkinson’s disease for over a decade. As the patient voice for Adamant Health, he will share his personal experience of life with Parkinson's disease to provide support, inspiration, and practical advice for others affected by the condition.

We are participating in Liikehäiriöpäivät 2025, organized by the Movement Disorder Division of the Finnish Neurological Society. Come visit us at our stand to learn more about our research-based data-analysis technology, providing detailed and accurate symptom data essential for supporting personalized Parkinson's disease treatment.

We have been working with our supplier to enhance the measurement device for the Adamant Health measurement and analysis service and developing our software application to make our service even easier for healthcare professionals to use. In addition, we have released a new patient diary, particularly developed for people with Parkinson’s disease.

2024 has been an extraordinary year for Adamant Health. As the year draws to a close, we’d like to thank you for your cooperation and support throughout the year. As we pause to spend time with family and friends during the holidays, we wish you a happy, healthy holiday season and a wonderful New Year!

A central topic of the 97th Congress of the German Neurological Society was motor complications and their frequency and management during the course of the disease. Parkinson's patients typically experience a range of motor symptoms during the course of their illness. According to a recent study, in the advanced stage of the disease, motor fluctuations have the highest impact on daily activities and the patient’s quality of life.

Adamant Health’s unique CE-marked data-analysis technology, based on surface electromyography and kinematic measurements, provides detailed and accurate symptom data. The easy-to-read symptom report includes a graphic visualization of the changes in the patient’s condition, an overview of the detected symptoms and their timing, and a summary of the symptoms reported by the patient.

By measuring the motor symptom itself and combining surface electromyography with motion sensor data, this future approach enables unparalleled accuracy in symptom assessment and provides clinically meaningful and actionable data for treatment planning.

The new patient diary, particularly developed for the Adamant Health measurement and analysis service, offers an easy and secure way to collect accurate information on the patient's medication intakes, symptoms, and well-being for clinical use.

Lately, the need for objective measurement to assess Parkinson's disease symptoms and treatment efficacy has emerged. Clinical assessment will continue to be essential in the diagnosis and treatment of the disease, but also modern technology, including wearable devices and artificial intelligence, will play a crucial role in the early detection of the disease and improving treatment effectiveness.

We are participating in the 97th Congress of the German Neurological Society, which will take place in Berlin, Germany from 6 - 9 November 2024. Visit us at booth B67 and learn how our technology can support you in the treatment of your patients!

We are participating in the Neurologipäivät 2024, the annual event of the Finnish Neurological Society, which will be organized in Helsinki from 30 October to 1 November 2024. Visit us at our booth and learn more about how our technology and service support earlier detection and accurate assessment of Parkinson's symptoms.

We are proud that Adamant Health is one of twelve selected Finnish healthcare companies for the AMPlify – Accelerated US Market Entry program 2024. The program designed by Business Finland in collaboration with Mayo Clinic aims to support Finnish healthcare companies in accessing the US market and shorten their time to market.

The annual congress of the European Academy of Neurology has become a premier platform for presenting cutting-edge neurological research and innovation, and exchanging knowledge. During this year's conference, a growing and active interest in the field of movement disorders, particularly Parkinson's disease, became evident with a clear call to evolve the way we diagnose and treat the disease.

Parkinson’s disease presents clinicians with unique challenges with its progressive nature and varied symptomatology. Our latest white paper explores the evolution of PD assessment methods. It presents the transformative potential of objective measurements for making better-informed decisions to improve patient outcomes.

There are many different symptoms associated with Parkinson's disease and the order in which these develop and their severity is different for each individual. Usually, the symptoms start mildly and develop gradually. Parkinson's disease symptoms are distinguished between motor symptoms and non-motor symptoms.

Meet us at the 10th Congress of the European Academy of Neurology to learn more about our data-driven approach to managing Parkinson’s disease, and how it will help people with Parkinson’s to get the best treatment possible – improving their quality of life!

Tekniikan Maailma features ten Finnish health technology companies providing innovative solutions for the benefit of the patient – Adamant Health with its unique measurement and analysis service for Parkinson's disease being one of them.

Parkinson’s disease is a progressive neurological disorder that is caused by the degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement, resulting in tremors, slowness of movement, rigidity, and impaired balance and coordination – the primary symptoms of the disease.

The gold standard for evaluating Parkinson’s disease symptoms has primarily relied on subjective assessments during in-clinic visits using rating scales like the Unified Parkinson’s Disease Rating Scale (UPDRS). This approach, however, has specific limitations, leading to often incomplete disease progression evaluation. Over the last decades, various methods have been developed to assess the patients' motor symptoms more accurately.